期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 324, 期 1-2, 页码 190-194出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2012.11.004
关键词
Mefloquine; JC virus; Progressive multifocal leukoencephalopathy; Human immunodeficiency virus; Blood-brain barrier; CD4
资金
- Research Committee of Prion Disease and Slow Virus Infection [H20-Nanchi-Ippan-013]
- Ministry of Education, Science, Sports and Culture of Japan [19790349, 22790446]
- Ministry of Health, Labour and Welfare of Japan [H24-AIDS-Wakate-002]
- Grants-in-Aid for Scientific Research [22790446, 19790349] Funding Source: KAKEN
Although progressive multifocal leukoencephalopathy (PML) cases showing responses to mefloquine therapy have been reported, the efficacy of mefloquine for PML remains unclear. We report on the failure of mefloquine therapy in two Japanese patients with PML unrelated to human immunodeficiency virus. One of the patients was a 47-year-old male who had been treated with chemotherapy for Waldenstrom macroglobulinemia, and the other was an 81-year-old male with idiopathic CD4(+) lymphocytopenia. Diagnosis of PML was established based on MRI findings and increased JC virus DNA in the cerebrospinal fluid in both patients. Mefloquine was initiated about 5 months and 2 months after the onset of PML, respectively. During mefloquine therapy, clinical and radiological progression was observed, and JC virus DNA in the cerebrospinal fluid was increased in both patients. Both patients died about 4 months and 2 months after initiation of mefloquine, respectively. Further studies are necessary to clarify the differences between mefloquine responders and non-responders in PML (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据